KYDES Pharmaceuticals

Product Pipeline

KYDES products are developed from currently approved drug compounds and FDA approved excipients using our proprietary technologies. The products will be manufactured to meet or exceed Current Good Manufacturing Practices (CGMP) Guidelines set forth by the FDA and other Regulatory Agencies. The products listed in the menu above are in various stages of development.

Click on the products below for details.

KY1107: Abuse deterrent opiate formulations

The need to treat pain with the most effective agents such as opiates while minimizing the risk of abuse and addiction became apparent shortly after the introduction of opiates into pharmaceutical/ medical use several centuries ago. From archeological digs, the earliest use of opiates dates back over 30,000 years to the Neanderthals while recorded use of opium dates to 3500 BC by the Sumerians. Basically, throughout history, opiates have wrecked havoc on the people of several nations and civilizations and the need for risk mitigation approaches that optimize their risk-benefit ratio is as dire today as it has been since antiquity. This situation was not without effort. Most of the initial efforts concentrated on medicinal chemistry to synthesize new compounds that can be used to treat pain without abuse. Although the synthetic approach have to date largely failed, some compounds such as peripherally active opiates are being investigated and their usefulness in the treatment of all types of pain where centrally active opiates are known to be effective remains to be seen.

With the failure of synthetic approaches, abuse-deterrent formulations (ADFs) have emerged as a means for supporting access to opiates for pain management while limiting abuse and its consequences. Several different types of ADFs have emerged including physical barriers to tampering, agonist-antagonist formulations, aversion-inducing combination, pro-drugs that target peripheral opiate receptors, and alternative methods of administration. While each of these types theoretically, has the potential to reduce specific forms of prescription opiate abuse, they will require not only technically successful formulations, but also appropriate scientific assessment, widespread market penetration, and rational expectations of their benefits.

With the failure of synthetic approaches, abuse-deterrent formulations (ADFs) have emerged as a means for supporting access to opiates for pain management while limiting abuse and its consequences. Several different types of ADFs have emerged including physical barriers to tampering, agonist-antagonist formulations, aversion-inducing combination, pro-drugs that target peripheral opiate receptors, and alternative methods of administration. While each of these types theoretically, has the potential to reduce specific forms of prescription opiate abuse, they will require not only technically successful formulations, but also appropriate scientific assessment, widespread market penetration, and rational expectations of their benefits.

KYDES is developing patentable oral products that are designed to minimize tampering as well as reduce the overdose potential of opiates for use in the management of severe pain.